Figure 3.

Synergistic effects of PIM1 inhibition and glucocorticoid therapy. (A) Western blot analysis of MCL1 protein levels in ex vivo treated xenograft spleen cells obtained from TCRβ-PIM1⁺ T-LBL, TLX3⁺ PIM1^high T-cell acute lymphoblastic leukemia (T-ALL) and SIL-TAL1⁺ PIM1^low T-ALL patients treated with PIM1 inhibitor TP-3654. (B) Combination treatment of TP-3654 and dexamethasone (72 hours) on an ex vivo co-culture system using tumor material from the TLX1⁺ TCRβ-PIM1⁺ T-cell lymphoblastic lymphoma (T-LBL) patient. Color code is based on the number of living cells per well. (C) Treatment schedule of in vivo combination treatment with TP-3654 and dexamethasone; 6 mice per group were used. (D) %hCD45 cells in peripheral blood during treatment for the different treatment groups. n.s.: not significant. ^*P<0.05; ^**P<0.01. (E) Kaplan-Meier curve representing survival during the in vivo combination drug treatment experiment.